QIAGEN Launches QIAsphere Cloud-Based Connectivity Solution to Enhance QIAstat-Dx Capabilities in Digital Diagnostics
March 03 2021 - 4:10PM
Business Wire
- Major step towards bringing customer service to critical and
syndromic testing
- QIAsphere mobile App enables real-time and remote test
monitoring from anywhere, and will be available for additional
QIAGEN instruments in coming months
- QIAstat-Dx customers can benefit from 24/7 remote service to
enhance testing continuity
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has launched
its QIAsphere cloud-based platform that will allow labs and
QIAstat-Dx users to monitor tests and instrument status remotely 24
hours a day, 7 days a week.
QIAsphere sets new standards for syndromic testing digital
health, providing users with remote visibility of their testing
routine. It can monitor a nearly unlimited number of instruments,
providing visibility of testing routine across different hospitals
or satellite labs. The continuous connectivity to QIAGEN service
reduces systems downtime and enabling fast and accurate syndromic
testing. Digital diagnostics and remote analytics will be crucial
to bring syndromic testing closer to patients in the coming
years.
Customers using QIAsphere will be able to remotely monitor their
QIAstat-Dx instrument and test status, received push notifications
across their personal devices, such as smartphones, desktop PCs and
smartwatches.
QIAstat-Dx connectivity with QIAsphere will also allow QIAGEN
technical service to monitor customers instruments health in
real-time, whilst providing them with rapid response to minimized
systems downtime.
QIAGEN began marketing and distributing QIAsphere for the
QIAcube Connect platform in early 2021 and will expand its scope
into Molecular Diagnostics with its syndromic testing platform
QIAstat-Dx. QIAGEN plans to extend the scope of QIAsphere across
many platforms and solutions in the coming months.
“The launch of QIAsphere platform for QIAstat-Dx is a key step
in syndromic testing, but above all for our customers: it is our
commitment to make their life easier, their testing workflow more
manageable and our interactions faster,” said Jean-Pascal Viola,
Senior Vice President, Head of the Molecular Diagnostics Business
Area and Corporate Business Development at QIAGEN. “Digital
diagnostics sets a new paradigm in syndromic testing. It addresses
the growing need of bringing molecular PCR COVID testing closer to
patients and to decentralized environments such as ICUs, emergency
rooms or satellite labs.”
QIAsphere connectivity is possible by connecting the QIAsphere
Base (Qbase), a small connectivity hub, to QIAstat-Dx and other
QIAGEN platforms in minimal time through hospitals LAN or Wifi
network, keeping sensitive patients data within the hospital
network. The Qbase connectivity hub along with QIAsphere App will
enable real-time monitoring across all customers QIAstat-Dx
analyzers.
For more information on QIAsphere please visit
https://www.qiagen.com/clp/qiasphere.
Further information on QIAGEN’s response to the coronavirus
outbreak can be found here.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare) and
Life Sciences (academia, pharma R&D and industrial
applications, primarily forensics). As of December 31, 2020, QIAGEN
employed more than 5,600 people in over 35 locations worldwide.
Further information can be found at http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, collaborations markets, strategy or operating
results, including without limitation its expected adjusted net
sales and adjusted diluted earnings results, are forward-looking,
such statements are based on current expectations and assumptions
that involve a number of uncertainties and risks. Such
uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating
results and allocations between customer classes, the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and
timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties
in successfully adapting QIAGEN's products to integrated solutions
and producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products and the integration of acquired technologies and
businesses. For further information, please refer to the
discussions in reports that QIAGEN has filed with, or furnished to,
the U.S. Securities and Exchange Commission (SEC).
Category: Corporate
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210303005962/en/
QIAGEN Investor Relations John Gilardi, +49 2103
29 11711 Phoebe Loh, +49 2103 29 11457 ir@QIAGEN.com
Public Relations Thomas Theuringer, +49 2103 29 11826
Robert Reitze, +49 2103 29 11676 pr@QIAGEN.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024